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Kinase-independent role for CRAF-driving tumour
radioresistance via CHK2
Sunil J. Advani1,*, Maria Fernanda Camargo2,*, Laetitia Seguin2, Ainhoa Mielgo2, Sudarshan Anand2,
Angel M. Hicks1, Joseph Aguilera1, Aleksandra Franovic2, Sara M. Weis2 & David A. Cheresh2
Although oncology therapy regimens commonly include radiation and genotoxic drugs,
tumour cells typically develop resistance to these interventions. Here we report that
treatment of tumours with ionizing radiation or genotoxic drugs drives p21-activated kinase 1
(PAK1)-mediated phosphorylation of CRAF on Serine 338 (pS338) triggering a kinase-
independent mechanism of DNA repair and therapeutic resistance. CRAF pS338 recruits
CHK2, a cell cycle checkpoint kinase involved in DNA repair, and promotes CHK2
phosphorylation/activation to enhance the tumour cell DNA damage response. Accordingly,
a phospho-mimetic mutant of CRAF (S338D) is sufﬁcient to induce the CRAF/CHK2
association enhancing tumour radioresistance, while an allosteric CRAF inhibitor sensitizes
tumour cells to ionizing radiation or genotoxic drugs. Our ﬁndings establish a role for CRAF in
the DNA damage response that is independent from its canonical function as a kinase.
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O
ncogenic or stimulated RAS family GTPases are capable
of triggering the growth and progression of a wide
range of cancers. RAS activation drives critical down-
stream effectors (including PI3K, BRAF/CRAF and RAL) that
not only potentiate tumour cell proliferation, and survival but
also induce resistance to a wide range of therapeutics1–4. Thus, it
is not surprising that targeting RAS or its effectors can sensitize
tumours to the effects of genotoxic stress5,6. Consistent with
the ﬁnding that CRAF becomes phosphorylated in response to
ionizing radiation7, expression of CRAF anti-sense oligo-
nucleotides leads to increased cellular radio-sensitivity8 and a
liposomal formulation of the RAF anti-sense oligonucleotide
LErafAON has shown promise when used in combination with
radiation therapy for patients with advanced malignancies9.
However, targeting of RAF or MEK with multi-kinase inhibitors
appears to provide sensitization in some cases10–12 but not
others13,14, which may be due to the non-speciﬁc nature of kinase
inhibitors.
In addition to its well-known role as a kinase upstream of
MEK, recent studies have uncovered a role for RAF as an adapter
protein that is independent of its kinase activity15. CRAF
phosphorylation on Serine 338 (due to P21-activated kinases)
promotes CRAF association with and inactivation of the
pro-apoptotic kinases ASK1 (ref. 16) and MST2 (ref. 17). CRAF
forms similar complexes with ROK-a to drive cell motility18 and
the cell cycle kinase PLK1 to drive cells through the G2/M cell
cycle checkpoint19. To perturb these kinase-independent
functions of CRAF, we developed an allosteric inhibitor of
CRAF designed to stabilize its inactive conformation and
block CRAF phosphorylation on S338 (ref. 20). This agent
prevents CRAF coupling to PLK1, leading to cell cycle arrest in
mitosis19. Given the relationship between cell cycle progression
and DNA repair21, we considered whether CRAF pS338 might
inﬂuence the DNA damage response.
Here we report that exposing tumours to radiation or
genotoxic drugs induces a p21-activated kinase 1 (PAK1)-
mediated phosphorylation of CRAF on S338, driving a complex
between CRAF and CHK2 to promote DNA repair. Accordingly,
inhibition of CRAF pS338 (but not its kinase activity) sensitizes
tumour cells to radiation and genotoxic drugs by increasing
the level of DNA damage. These results highlight an opportunity
to target this resistance mechanism to sensitize tumours to
the DNA-damaging effects of cancer therapy, potentially lowering
the chemotherapy or radiation dose required to achieve tumour
killing.
Results
CRAF protects cells from DNA damage. Given the well-
established role for RAS activity in tumour cell resistance to
therapy, we examined the relative contribution of the RAF
family kinases BRAF and CRAF to radioresistance. Mouse
embryonic ﬁbroblasts isolated from BRAF / or CRAF /
mice were exposed to radiation and monitored for DNA
damage by examining the level of nuclear gH2AX foci. Only
those cells deﬁcient in CRAF showed radiosensitivity (Fig. 1a,
Supplementary Fig. 1a), suggesting that CRAF but not BRAF
contributed to radioresistance. We extended these studies
by knocking down either CRAF or BRAF in HCT-116 human
colorectal adenocarcinoma and PANC-1 human pancreatic
adenocarcinoma cells and measured cell survival and DNA
damage following irradiation (Fig. 1b, Supplementary Fig. 1b,c).
In irradiated HCT-116 cells, knockdown of CRAF decreased
cell survival. In addition, knockdown of CRAF in PANC-1 cells
increased DNA damage as measured by neutral comet assay. In
contrast, knockdown of BRAF in HCT-116 and PANC-1 cells had
no such effect. While CRAF was required for radioresistance,
MEK inhibition did not result in radiosensitization consistently
(Supplementary Fig. 2). These ﬁndings suggest that, while CRAF
protects cells from DNA damage, this function may not require
CRAF kinase activity or MEK activation.
DNA damage triggers phosphorylation of CRAF on Serine 338.
Recent studies indicate that CRAF phosphorylated on S338
potentiates cell cycle progression, cell survival and motility in a
manner that is independent of its kinase activity15,16,18,19. Given
the relationship between cell cycle progression and DNA repair,
we considered whether the DNA damage response might
depend in part on CRAF pS338. Radiation of HCT-116 or
PANC-1 cells speciﬁcally resulted in increased pS338 CRAF
relative to untreated cells (Fig. 1c. Supplementary Fig. 3a).
However, other phosphorylation sites on CRAF such as, pS259,
pS301 or BRAF pT599 did not increase in response to radiation
treatment. Furthermore, radiation treatment produced a strong
dose-dependent induction of CRAF pS338 (Fig. 1d). Treatment of
HCT-116 and U87 (glioblastoma) cells with the DNA-damaging
cancer therapy Etoposide produced a similar CRAF pS338 dose-
dependent response, suggesting that CRAF becomes
phosphorylated on S338 in response to genotoxic stress (Supple-
mentary Fig. 3b). To establish the physiological relevance of these
ﬁndings, HCT-116 tumour xenografts established in mice were
locally irradiated with a single dose of 6Gy ionizing radiation
(IR), harvested 2 h later, sectioned and stained for CRAF pS338.
In accordance with our in vitro ﬁndings, tumours exposed to IR
showed a marked increase in CRAF pS338 (Fig. 1e).
CRAF pS338 is necessary and sufﬁcient for radioresistance. We
previously described a type II allosteric RAF inhibitor that
stabilizes RAF in the inactivate state, known as compound 6
(ref. 20) or KG5 (ref. 19) that inhibits CRAF pS338 in various cell
types. Importantly, KG5 suppressed the radiation-induced CRAF
pS338 cytoplasmic staining in HCT1-116 and PANC-1 cells
(Fig. 1c,f, Supplementary Fig. 4). Other phosphorylation sites on
CRAF and BRAF were diminished to some degree following
treatment with KG5 which is not surprising considering the
fact that KG5 is an allosteric inhibitor of RAF and blocks
the dimerization of BRAF and CRAF20 thereby preventing
co-activation of these molecules. While KG5 interferes with
various phosphorylation sites on RAF, only CRAF pS338 is
upregulated in response to IR (Fig. 1c). Consistent with a role for
CRAF pS338 in radioresistance, treatment of HCT-116 and
PANC-1 cells with KG5 not only decreased clonogenic survival in
response to IR, but it also markedly enhanced the DNA damage
response as detected by an increased comet tail length and
gH2AX foci formation (Fig. 1g, Supplementary Fig. 4).
To validate the role of CRAF pS338 in radioresistance,
HCT-116 cells expressing a phospho-mimetic mutant of CRAF
(S338D) or full-length wild-type (WT) CRAF were exposed to IR
and examined for cell survival and DNA damage. Expression of
CRAF S338D protected cells from IR-induced damage compared
with cells expressing WT CRAF (Fig. 2a, Supplementary Fig. 5),
suggesting that CRAF pS338 is sufﬁcient to promote
radioresistance. To validate this ﬁnding in vivo, mice were
implanted with HCT-116 tumours (expressing either WT or
S338D CRAF) on bilateral ﬂanks, and only the right ﬂank was
subjected to localized 6Gy radiation on days 5, 7 and 9 after
tumour implantation. While irradiation inhibited the growth of
tumours expressing WT CRAF, tumours expressing CRAF S338D
continued to grow (Fig. 2b) indicating that the phospho-mimetic
CRAF mutant is sufﬁcient to protect tumours from radiation
damage.
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Figure 1 | CRAF pS338 is induced by genotoxic stress and protects tumour cells from DNA damage. (a) Embryonic ﬁbroblasts isolated from wild-type
(WT), BRAF/ or CRAF/ mice were irradiated (6Gy), and DNA damage was assessed using gH2AX staining. Graph shows mean gH2AX
foci/cell±s.e.m. for n¼ 6 ﬁelds analysed per group. ‘*’ indicates Po0.05 from two-sided t-test comparing WT and CRAF/ . Data shown are
representative of two independent experiments. (b) HCT-116 cells were transfected with siRNA to BRAF and CRAF. Cells were irradiated (2Gy) and cell
survival was measured using clonogenic survival assay. Graph shows mean surviving fraction±s.e.m. ‘*’ indicates Po0.05 from two-sided t-test comparing
si-CRAF to si-BRAF, si-CTRL or non-transfected with n¼ 3 wells per group. Data shown are representative of three independent experiments. (c) HCT-116
cells treated with KG5 (1mm) overnight, irradiated (6Gy) and whole cell lysates collected. Immunoblotting to indicate phospho CRAF and BRAF sites. Data
shown are representative of three independent experiments. (d) Immunoblotting for pS338 CRAF following 6Gy or 0.5 mM etoposide. Immunostaining for
CRAF pS338 (green) with dose range of IR in HCT-116 cells. Nuclei were counterstained with DAPI (blue). Scale bar, 20mm. Data shown are representative
of ﬁve ﬁelds per group for two independent experiments. (e) HCT-116 xenograft tumours were irradiated (6Gy) and then immunostained for CRAF pS338
(green). Nuclei were counterstained with DAPI (blue). Scale bar, 100mm. Data shown are representative of n¼4 mice per group, four ﬁelds per mouse, for
two independent experiments. (f) Immunostaining for CRAF pS338 (green) in HCT-116 cells treated with KG5 (1mM) overnight then irradiated (6Gy).
Nuclei were counterstained with DAPI (blue). Scale bar, 20mm. Data shown are representative of n¼ 5 ﬁelds per group for two independent experiments.
(g) HCT-116 cells were treated with KG5 and then irradiated. DNA double strand breaks were measured by neutral comet tail assay (n¼ 100þ cells per
group). Cell survival was measured using a clonogenic assay (n¼ 3 wells per group). Bars represent mean±s.e.m. *Po0.05 from two-sided t-test
comparing vehicle control and KG5. Data are representative of two independent experiments.
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To conﬁrm this ﬁnding and explore whether CRAF kinase
activity was not required for radioprotection, U87 human
glioblastoma cells expressing either WT CRAF or a double
mutant phospho-mimetic/kinase-dead CRAF mutant (S338D/
K375M) were subjected to IR. As previously shown, U87 cells
expressing WT CRAF showed IR-induced phosphorylation of
MEK, while those expressing the double mutant (S338D/375M)
lacking CRAF kinase activity did not (Supplementary Fig. 6).
This is consistent with the notion that this mutant CRAF is
acting as a dominant negative. Importantly, cells expressing
the CRAF S338D/K375M double mutant showed increased
survival and reduced DNA damage following IR compared
with cells expressing WT CRAF (Fig. 2c). We conﬁrmed
these results by transfecting CRAF null MEFs with WT or
single mutants S338A, S338D or K375M CRAF. Null MEFs
expressing WT CRAF or S338A had more DNA damage (gH2AX
foci/cell) than cells expressing S338D CRAF (Fig. 2d,
Supplementary Fig. 7). The K375M kinase-dead mutation
produced only a slight increase in DNA damage over the control,
further suggesting that S338 plays a predominant role in
CRAF-mediated protection from DNA damage. These ﬁndings
support the notion that CRAF pS338 is critical for DNA repair,
while CRAF kinase activity is not.
PAK1 activates CRAF pS338 and modulates radiosensitivity.
Previous studies have shown that CRAF S338 phosphorylation
depends on one or more members of the PAK family22–25.
Therefore, we considered whether radiation or etoposide
treatment of tumour cells would stimulate PAK activation that,
in turn, would lead to CRAF pS338 and its capacity to trigger the
DNA damage response. Accordingly, we found that treatment of
HCT-116 cells either in vivo or in vitro with IR or etoposide
resulted in enhanced activation of PAK1 and PAK2 as measured
by pS141 immunoreactivity (Fig. 3a,b). Interestingly, knockdown
of PAK1 (but not PAK2 or PAK4) completely abolished CRAF
pS338 (Fig. 3c), and this was accompanied by a dramatic increase
in IR-mediated DNA damage (Fig. 3d). Moreover, expression of
constitutively active PAK1 (L017F), which increased pS338
CRAF, enhanced cell survival following radiation (Fig. 3e).
Together, these ﬁndings indicate that DNA damage leads to
PAK1 activation, resulting in CRAF pS338 and DNA repair.
CRAF protects cells from DNA damage by activating CHK2.
An orchestrated series of genes regulate the response to the
DNA-damaging effects of radiation26,27. To consider how CRAF
pS338 might mediate radioprotection, RNA was extracted
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Figure 2 | CRAF kinase activity is not required to drive radioresistance. (a) HCT-116 cells were stably transfected to express wild-type CRAF (WT) or
the phospho-mimetic CRAF S338D mutant. Cells treated with or without 6Gy were analysed for DNA damage using clonogenic (*P¼0.012, n¼ 3 wells per
group, two-sided t-test) and comet tail assays (Po0.0001, n¼ 100þ cells per group, two-sided t-test). Bars represent mean±s.e.m. Data are
representative of two independent experiments. (b) Immune-compromised nu/nu mice were implanted s.c. with tumour cells to each thigh, and only the
right thigh received three fractions of 6Gy on Days 5, 7 and 9. Graph shows mean tumour volume±s.e.m, *P¼0.04 from two-sided t-test comparing
WTþ IR (n¼ 10) versus S338Dþ IR (n¼ 9) at the endpoint on Day 15. (c) Stably transfected U87 cells expressing wild-type CRAF (WT) or the
CRAF kinase-dead, phospho-mimetic double mutant (S338D/K375M) were exposed to 6Gy. DNA damage was assessed by clonogenic (P¼0.002, n¼ 3
wells per group), comet tail (*P¼0.0005, n¼ 100þ cells per group) and gH2AX assays (*P¼0.0007, n¼6 ﬁelds per group). All bar graphs show
mean±s.e.m. P values from two-sided t-tests comparing WT versus each CRAF mutant. Data are representative of two independent experiments.
(d) CRAF/ MEFs were transfected with GFP-tagged WT, S338A, S338D or K375M CRAF for 72 h and then given 6Gy. DNA damage was assessed
using gH2AX staining. Graph shows mean gH2AX foci per cell±s.e.m. for n¼ 50þ cells analysed per group. *Po0.05 from two-sided t-test comparing
WT and CRAF/ . Data are representative of three independent experiments.
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from U87 glioblastoma cells expressing WT CRAF or the K375M/
S338D double mutant and analysed using a reverse transcription–
PCR (RT–PCR) array involving 92 genes with known roles in
response to DNA damage. Of the 92 genes examined, 6 showed a
42-fold increase in cells expressing the CRAF double mutant
relative to WT. These include ATM, ATR, BRCA1, BRCA2,
RAD17 and POLK, all of which were validated
by RT–PCR (Supplementary Fig. 8). Since the checkpoint
kinases CHK1/CHK2 are activated by ATR/ATM and their
downstream activity is modulated by BRCA1/BRCA2 (refs 28,29),
we examined the effect of the K375M/S338D mutation on
CHK1/CHK2 activity. While the radiation-induced increase in
active CHK1 (pS345) was similar for cells expressing WT CRAF
or the CRAF K375M/S338D double mutant, active CHK2 (pT68)
was upregulated twofold in cells expressing the CRAF double
mutant (Fig. 4a). These ﬁndings suggest that activation of
CHK2, a well-known contributor to radioresistance30–33, may
partly account for the radio-protective effect of CRAF S338
phosphorylation.
Given that phosphorylation of S338 potentiates CRAF
scaffolding function16,19, and the CRAF K375M/S338D double
mutant leads to increased CHK2 T68 phosphorylation, we
considered whether CRAF might interact with CHK2. While
CRAF co-precipitated with CHK2 to some degree in non-treated
cells, this interaction was markedly increased following
cell exposure to radiation and included active pCHK2 (Fig. 4b).
Pre-treating cells with KG5 served to decrease both the levels of
CRAF pS338 and the CRAF/CHK2 association (Fig. 4c). CHK2
was able to associate with CRAF, but not with BRAF (Fig. 4c),
consistent with our ﬁndings that BRAF expression was
not required for radio-resistance (Fig. 1a,b). Furthermore, the
CRAF/CHK2 association was enhanced in non-irradiated cells
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expressing the CRAF S338D phospho-mimetic mutation
compared with cells expressing WT CRAF (Supplementary
Fig. 9), suggesting that phosphorylation of CRAF on S338
contributes to its interaction with CHK2. To test whether
CHK2 expression was required to promote the radio-protective
effects of CRAF, we knocked down CHK2 in cells expressing
either WT or S338D CRAF and exposed these cells to radiation.
While CRAF S338D promoted radioprotection in control cells,
knockdown of CHK2 completely reversed this effect (Fig. 4d).
Together, these results support the notion that CRAF-mediated
radioprotection depends on the ability of pS338 to couple to and
facilitate the activation of CHK2, explaining why targeting CRAF
pS338 can sensitize cells to DNA damage.
Discussion
Accumulating evidence suggests that CRAF operates in a kinase-
independent (and therefore MEK independent) manner to
inﬂuence cellular behaviour by functioning as a molecular
scaffold15,16,19. In particular, CRAF phosphorylation on S338
appears to contribute to CRAF scaffolding function15,16,19, leading
to enhanced tumour cell proliferation19 and a signiﬁcant decrease
in the survival of breast cancer patients34. Consistent with this
concept of a kinase-independent scaffolding function of CRAF, the
DNA damage response mediated by CHK2 appears to depend on
CRAF pS338 but not its kinase activity. CHK2 activity depended in
part on its capacity to couple to CRAF pS338, however, CHK2
activation and DNA repair were not inhibited by a kinase-dead
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form of CRAF. In contrast to traditional RAF inhibitors that target
its ATP-binding pocket to block MEK/ERK signalling, KG5 is an
allosteric CRAF inhibitor that suppresses CRAF thereby disrupting
its scaffolding function to produce a signiﬁcant impact cell cycle
progression19, and as shown here, the DNA damage response
(Fig. 4e). While KG5 does not possess PK properties sufﬁcient for
clinical development, our results highlight the potential of such
drugs as a new class of agents with the capacity to sensitize
tumours to genotoxic therapies.
We have identiﬁed PAK1 as the upstream kinase that, in
response to genotoxic stress, is activated and phosphorylates S338
on CRAF leading to DNA repair in a CHK2-dependent manner.
PAKs respond to growth factor and integrin ligation, and their
activity leads to remodelling of the cytoskeleton necessary for cell
migration and invasion35,36. PAK family members have been
reported to be overexpressed and or deregulated in cancers and
have been linked to the DNA damage response pathway37. In fact,
PAK1 phosphorylation and activation in response to IR have
been linked to ATM, a key regulator of the DNA damage
response, and microarray expression proﬁling has revealed that
the primary group of genes regulated by PAK1 in response to
DNA damage is involved in cell cycle progression35.
It is not surprising that DNA repair is intimately linked to cell
cycle progression. On exposure to genotoxic stress, activation of
various checkpoint proteins helps to ensures DNA will be repaired
prior to resumption of the cell cycle. This is of paramount
importance during mitosis, as unrepaired DNA damage would be
propagated to daughter cells. Moreover, sensitivity to IR varies
throughout the cell cycle with the G2/M phase being the most
radiosensitive. These concepts are consistent with the roles we have
uncovered for CRAF in coordinating cell progression by activation
of PLK1 (ref. 19) and DNA damage repair via CHK2, both of
which depend on pS338 and operate in a kinase-independent
manner. The localization of CRAF pS338 at the spindle pole and
its association with PLK1 may limit its potential for interaction
with CHK2, thereby further contributing to the increased
radiosensitivity of cells undergoing mitosis.
A number of studies have revealed the ‘RAF inhibitor paradox’ in
which CRAF is activated and tumour growth enhanced for tumours
with activating mutations in KRAS but not BRAF. It has become
clear that ATP mimetic inhibitors of RAF drive dimerization of WT
BRAF and CRAF, lead to phosphorylation of CRAF on serine 338,
potentiate the MEK/ERK pathway and thereby contribute to the
observed increase in tumour growth38–40. Indeed, while genetic
knockdown of CRAF enhances cancer sensitivity to IR,
pharmacologically targeting CRAF with ATP mimetic inhibitors
often fails to radiosensitize tumours9,12,14. Unlike typical RAF
inhibitors that target the ATP-binding pocket, the allosteric RAF
inhibitor KG5 acts in a kinase-independent manner to block the
dimerization of BRAF/CRAF and phosphorylation of CRAF on
S338 (ref. 20). By virtue of their ability to induce cell cycle arrest in
G2/M by targeting PLK1 (ref. 19), and to dampen the DNA repair
response through the inhibition of CHK2 activity, allosteric RAF
inhibitors such as KG5 would be expected to have a broad
application for the sensitization of genetically diverse tumours to
the effects of cancer therapies such as ionizing radiation or
etoposide that function by inducing genotoxic stress.
Methods
Cell lines and reagents. HCT-116, PANC-1 and U87 human cancer cell lines were
obtained from ATCC within the last 5 years. Cell line authentication was performed by
the ATCC using short tandem repeat DNA proﬁles. On receipt, each cell line was
expanded, cryopreserved as low-passage stocks and tested routinely for mycoplasma
immediately before use in an experiment. KG5 was synthesized as previously described20.
Sorafenib was purchased from ChemieTek, and L-779450 was purchased from Tocris.
DMSO (Sigma) was used as a vehicle control for in vitro studies. 40% PEG400, 60%
water was used as a vehicle control for in vivo studies, delivered as 250ml oral gavage.
Antibodies. All primary antibodies used for immunostaining, blotting or
immunoprecipitation were purchased from commercial vendors, and were
provided with datasheets that validate use with human cells. Immunoblotting was
performed using the reagents and dilutions in Supplementary Table 1.
Mutant constructs and transfection. Generation of cells stably expressing the
WT CRAF, CRAF S338D and CRAF S338D/K375M constructs have previously
been described19. BRAF and CRAF expression was transiently silenced by
transfecting PANC-1 and HCT-116 cells with Qiagen BRAF (#SI02632945,
#SI02632959) or CRAF(#SI0222303, #SI01396220) short interfering RNA (siRNA)
constructs, CHK2 expression was transiently silenced by transfecting HCT-116
cells with a Qiagen CHK2 (#SI02655422, #SI02663857) siRNA, PAK1, PAK2 and
PAK4 expression was transiently silenced by transfecting HCT-116 cells with
Qiagen PAK1 (#SI00039781,#SI00039781), PAK2 (#SI00301077) and PAK4
(#SI00082341) siRNA, using lipofectamine 3000 (Invitrogen #L3000008) following
manufacturer’s instructions.
Immunoﬂuorescent staining. Cultured cells were ﬁxed in ice-cold methanol,
permeabilized in 0.1% Triton X-100, blocked in 2% BSA, incubated with primary
antibody at 1:100 dilution for 1 h at room temperature, washed and incubated in
secondary antibody at 1:500 for 2 h at room temperature. Frozen tissue sections
were ﬁxed in ice-cold acetone, blocked in 0.5% BSA, incubated with primary
antibody at 1:50–100 dilution overnight at 4 C, washed and incubated in
secondary antibody at 1:500 for 30min at room temperature. Samples for gH2AX
staining were exposed to 6Gy then 2 h later were ﬁxed in 3–4% paraformaldehyde,
permeabilized in 0.25% Triton X-100, blocked in 1% BSA, incubated with primary
antibody for 1 h at room temperature, washed and incubated in secondary antibody
for 1 h at room temperature. Samples were incubated for 1min in a 1:5,000 dilution
of TOPRO3 or DAPI to label nuclei. Number of foci per cell was counted for 6
ﬁelds per group, with an average of 12 cells per ﬁeld.
Surviving fraction following radiation. Clonogenic assays were performed to
determine the surviving fraction following exposure to 2Gy. Brieﬂy, cells were
irradiated and then harvested 1 h later. Cells were counted and then re-plated at
varying cell numbers. Colonies were counted 10–14 days after initial seeding in
plates that had 20–200 colonies. For KG5-treated cells, cells were treated with 1 mM
of KG5 for 16 h prior to exposure to 2Gy.
Comet tail assay for DNA damage. Ionizing radiation-induced DNA double
strand breaks were measured using neutral comet tail assay. Cells were radiated
(6Gy), harvested 15min after irradiation and then assayed using the Trevigen
CometAssay kit. Comet tail length in pixels was measured using CometScore
freeware (TriTek Corp). About 50–100 cells were analysed in each sample group.
Immunoprecipitation and immunoblotting. Lysates were made using a standard
NP-40 lysis buffer and protein concentration quantiﬁed using the Pierce BCA
kit (Thermo Scientiﬁc). About 30 mg protein was loaded onto denaturing SDS–
polyacrylamide gel, transferred to polyvinylidene diﬂuoride membranes, blocked
with 5% bovine serum albumin, incubated with primary antibodies overnight and
HRP-conjugated secondary antibodies for 1 h (see reagent list in Supplementary
Table 1), and bands detected by enhanced chemiluminescence (Pierce). Immu-
noprecipitation for CRAF was performed using CRAF-conjugated beads (Santa
Cruz #133) or Ultralink Protein A/G Beads (VWR, #P153133) using 500 mg of
protein. Uncropped scans of immunoblots are provided in Supplementary Fig. 10.
Animal models. All animal work was approved by the UCSD Institutional Animal
Use and Care Committee under protocol #S05018. Immune compromised 8–10-
week-old female nu/nu mice purchased from the UCSD Animal Care Program
breeding colony were injected s.c. to each thigh with ﬁve million mycoplasma-
negative HCT-116 tumour cells in Matrigel (BD Biosciences). Tumour growth was
measured with calipers, with volume computed as ½ lengthWidth2. Mice were
randomized into groups once the average tumour volume reached 150mm3, B8
days after injection. Any mice with tumours±1.5 times the s.d. were excluded, as
were any tumours without positive growth over the last 2 days before dosing. The
remaining mice were assigned to either non-irradiated or radiated (6Gy). Mice were
killed by CO2 overdose followed by cervical dislocation, then dissected tumours were
photographed, weighed and processed for biochemical and staining analyses.
Ionizing radiation. The J.L. Shepherd Mark I Cesium source irradiator in the
Moores UCSD Cancer Center Vivarium was used for all studies. Cells in tissue
culture plates were exposed to radiation of 2 or 6 Gy. Mice with tumours are placed
on a circular holder with the body shielded using a Cerrobend shield, and only the
tumour region on the thigh exposed. Mice are anesthetized with ketamine/xylazine
to ensure appropriate body shielding. The mice are exposed to a maximum of 6-Gy
radiation, at B2Gymin 1. These doses of radiation do not cause any
constitutional symptoms since the bone marrow, lymphatic system and GI tract are
not exposed.
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Experimental design and statistics. Samples were randomly assigned to groups or
alternating processing order when possible, and analysis for all in vitro and in vivo
experiments was performed blinded. For each assay and tumour experiment, data
generated from pilot studies were used to perform power analysis to determine
sample size. No samples or animals were excluded. All graphs depict mean±s.e.m.
Statistical signiﬁcance for all experiments was determined using a two-sided/equal
variance t-test, with no adjustments for multiple comparisons. All samples from each
group were analysed to conﬁrm a normal distribution and equal variance. Each
experiment was repeated at least twice to assure reproducibility.
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